Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2006-11
Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC).
ABSTRACT
We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.
Related Questions
We've seen quite a few patients present with NSCLC with a single brain metastasis and a good performance status. Would you advocate for an aggressive ...
New answer by Radiation Oncologist at Rutgers Robert Wood Johnson Medical School (October 10, 2014)
There are a couple of series that suggest that for patients with oligometastatic disease with Stage III disease in the chest, that these patients can achieve significant long-...